Biggest changeRESULTS OF OPERATIONS Years Ended December 31, 2024 2023 2022 (1) (in millions, except per share amounts) Net sales $ 1,981.1 $ 2,026.0 $ 1,636.9 Cost of products sold 1,617.0 1,670.2 1,330.9 Gross profit 364.1 355.8 306.0 Selling and general expense 233.8 263.9 254.9 Research and development expense 23.0 21.2 18.8 Intangible asset amortization expense 62.9 61.0 53.4 Total nonmanufacturing expenses 319.7 346.1 327.1 Goodwill impairment expense — 401.0 — Restructuring and other impairment expense 38.1 22.6 19.1 Operating profit (loss) 6.3 (413.9) (40.2) Interest expense 74.7 62.2 57.3 Loss on debt extinguishment 7.3 — — Other income (expense), net (3.2) (4.8) 1.0 Loss from continuing operations before income taxes (78.9) (480.9) (96.5) Income tax expense (benefit) (30.2) 26.8 (27.6) Net loss from continuing operations (48.7) (507.7) (68.9) Income from discontinued operations, net of tax — 198.2 62.3 Net loss $ (48.7) $ (309.5) $ (6.6) Net income (loss) per share from continuing operations Basic $ (0.90) $ (9.33) $ (1.64) Diluted $ (0.90) $ (9.33) $ (1.64) (1) Results during the year ended December 31, 2022 include Neenah from the July 6, 2022 acquisition date to December 31, 2022. 38 Comparison of the Years Ended December 31, 2024 and 2023 Net Sales The following table presents net sales by segment (in millions): 2024 2023 Change Percent Change FAM $ 766.5 $ 810.0 $ (43.5) (5.4) % SAS 1,214.6 1,216.0 (1.4) (0.1) % Total $ 1,981.1 $ 2,026.0 $ (44.9) (2.2) % Net sales of $1,981.1 million during the year ended December 31, 2024 decreased $44.9 million, or 2.2% compared to the prior year-end.
Biggest changeRESULTS OF OPERATIONS Years Ended December 31, 2025 2024 2023 (in millions, except per share amounts) Net sales $ 1,987.0 $ 1,981.1 $ 2,026.0 Cost of products sold 1,624.1 1,617.0 1,670.2 Gross profit 362.9 364.1 355.8 Selling and general expense 228.7 233.8 263.9 Research and development expense 23.6 23.0 21.2 Intangible asset amortization expense 63.2 62.9 61.0 Total nonmanufacturing expenses 315.5 319.7 346.1 Goodwill impairment expense 411.9 — 401.0 Restructuring and other impairment expense 19.9 38.1 22.6 Operating profit (loss) (384.4) 6.3 (413.9) Interest expense 71.1 74.7 62.2 Loss on debt extinguishment — 7.3 — Other expense, net (7.5) (3.2) (4.8) Loss from continuing operations before income taxes (463.0) (78.9) (480.9) Income tax expense (benefit) (125.6) (30.2) 26.8 Net loss from continuing operations (337.4) (48.7) (507.7) Income from discontinued operations, net of tax — — 198.2 Net loss $ (337.4) $ (48.7) $ (309.5) Net income (loss) per share from continuing operations Basic $ (6.19) $ (0.90) $ (9.33) Diluted $ (6.19) $ (0.90) $ (9.33) 39 Comparison of the Years Ended December 31, 2025 and 2024 Net Sales The following table presents net sales by segment (in millions): 2025 2024 Change Percent Change FAM $ 767.5 $ 766.5 $ 1.0 0.1 % SAS 1,219.5 1,214.6 4.9 0.4 % Total $ 1,987.0 $ 1,981.1 $ 5.9 0.3 % The following table presents components of change in net sales by segment for the year ended December 31, 2025 compared to 2024 (as a percentage of net sales): Percent Change in Net Sales FAM SAS Total Volume/mix 0.1 % 2.0 % 1.3 % Sales associated with exited facilities — (3.5) (2.1) Total volume/mix 0.1 (1.5) (0.8) Selling price (1.1) 1.0 0.2 Currency translation 1.1 0.9 0.9 Total percent change 0.1 % 0.4 % 0.3 % FAM segment net sales of $767.5 million during the year ended December 31, 2025 increased $1.0 million, or 0.1% compared to prior year-end.
The Indenture contains certain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to incur additional indebtedness, make certain dividends, repurchase Company stock or make other distributions, make certain investments, create liens, transfer or sell assets, merge or consolidate and enter into 45 transactions with the Company’s affiliates.
The Indenture contains certain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to incur additional indebtedness, make certain dividends, repurchase Company stock or make other distributions, make certain investments, create liens, transfer or sell assets, merge or consolidate and enter into transactions with the Company’s affiliates.
For the SAS segment, we generally expect to deliver growth relatively in line with long-term broad economic growth in the U.S. and to some extent Europe and China. 46 FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") that are subject to the safe harbor created by the Act and other legal protections.
For the SAS segment, we generally expect to deliver growth relatively in line with long-term broad economic growth in the U.S. and to some extent Europe and China. 47 FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") that are subject to the safe harbor created by the Act and other legal protections.
Refer to Note 13. Debt of the Notes to Consolidated Financial Statements, for more information. On February 10, 2021, we amended our Credit Agreement to, among other things, add a new seven-year $350.0 million Term Loan B Facility (the “Term Loan B Facility”) and to decrease the incremental loans that may be extended at the Company’s request to $250.0 million.
Debt of the Notes to Consolidated Financial Statements, for more information. On February 10, 2021, we amended our Credit Agreement to, among other things, add a new seven-year $350.0 million Term Loan B Facility (the “Term Loan B Facility”) and to decrease the incremental loans that may be extended at the Company’s request to $250.0 million. Refer to Note 12.
The determination of the forecasted financial covenants requires management to make significant estimates and assumptions related to forecasts of future cash flows, future net debt, and future benefits from Merger synergies.
The determination of the forecasted financial covenants requires management to make significant estimates and assumptions related to forecasts of future cash flows, future net debt, and future benefits from future synergies.
Future deterioration in these conditions may require us to perform an interim quantitative impairment test in 2025. The fair value estimates used in the assessment of impairment for goodwill consider historical trends in addition to significant assumptions including projections of future performance. Changes in these assumptions can have a significant impact on the assessment of fair value.
Future deterioration in these conditions may require us to perform an interim quantitative impairment test in 2026. The fair value estimates used in the assessment of impairment for goodwill consider historical trends in addition to significant assumptions including projections of future performance. Changes in these assumptions can have a significant impact on the assessment of fair value.
For a comparison of the Company’s results of operations for the year ended December 31, 2023 to the year ended December 31, 2022, refer to Item 7. "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the U.S.
For a comparison of the Company’s results of operations for the year ended December 31, 2024 to the year ended December 31, 2023, refer to Item 7. "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the U.S.
The Company was in compliance with all of its covenants under the Indenture at December 31, 2024. For a comparison of liquidity and capital resources and the Company’s cash flow activities for the fiscal year ended December 31, 2023 and 2022, refer to Item 7.
The Company was in compliance with all of its covenants under the Indenture at December 31, 2025. For a comparison of liquidity and capital resources and the Company’s cash flow activities for the fiscal year ended December 31, 2024 and 2023, refer to Item 7.
As discussed in Note 9. Discontinued Operations of the Notes to Consolidated Financial Statements, the results from continuing operations exclude the results of our EP Business for all periods presented. All information presented within this MD&A is on a continuing operations basis.
As discussed in Note 8. Discontinued Operations of the Notes to Consolidated Financial Statements, the results from continuing operations exclude the results of our EP Business for all periods presented. All information presented within this MD&A is on a continuing operations basis.
Changes in these factors could materially impact our financial condition, results of operations, and our cash flows. For further information, refer to "Litigation" in Part I, Item 3, "Legal Proceedings" and Note 19.
Changes in these factors could materially impact our financial condition, results of operations, and our cash flows. For further information, refer to "Litigation" in Part I, Item 3, "Legal Proceedings" and Note 18.
The Company was in compliance with all of its covenants under the amended Credit Agreement at December 31, 2024. With the current level of borrowing and forecasted results, we expect to remain in compliance with our amended Credit Agreement financial covenants.
The Company was in compliance with all of its covenants under the amended Credit Agreement at December 31, 2025. With the current level of borrowing and forecasted results, we expect to remain in compliance with our amended Credit Agreement financial covenants.
Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance unless expressed as such and should only be viewed as historical data. 48
Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance unless expressed as such and should only be viewed as historical data. 49
Risk Factors of this report, as well as the following factors: • Risks associated with the implementation of our strategic growth initiatives, including diversification, and the Company's understanding of, and entry into, new industries and technologies; • Risks associated with acquisitions, dispositions, strategic transactions and global asset realignment initiatives of Mativ; • Adverse changes in our end-market sectors impacting key customers; • Changes in the source and intensity of competition in our commercial end-markets; • Adverse changes in sales or production volumes, pricing and/or manufacturing costs; • Seasonal or cyclical market and industry fluctuations which may result in reduced net sales and operating profits during certain periods; • Risks associated with our technological advantages in our intellectual property and the likelihood that our current technological advantages are unable to continue indefinitely; • Supply chain disruptions, including the failure of one or more material suppliers, including energy, resin, fiber, and chemical suppliers, to supply materials as needed to maintain our product plans and cost structure; • Increases in operating costs due to inflation and continuing increases in the inflation rate or otherwise, such as labor expense, compensation and benefits costs; • Our ability to attract and retain key personnel, labor shortages, labor strikes, stoppages or other disruptions; • Changes in general economic, financial and credit conditions in the U.S., Europe, China and elsewhere, including the impact thereof on currency exchange rates (including any weakening of the Euro) and on interest rates; • A failure in our risk management and/or currency or interest rate swaps and hedging programs, including the failures of any insurance company or counterparty; • Changes in the manner in which we finance our debt and future capital needs, including potential acquisitions; • Changes in tax rates, the adoption of new U.S. or international tax legislation or exposure to additional tax liabilities; • Uncertainty as to the long-term value of the common stock of Mativ; • Changes in employment, wage and hour laws and regulations in the U.S. and elsewhere, including unionization rules and regulations by the National Labor Relations Board, equal pay initiatives, additional anti-discrimination rules or tests and different interpretations of exemptions from overtime laws; 47 • The impact of tariffs, and the imposition of any future additional tariffs and other trade barriers, and the effects of retaliatory trade measures; • Existing and future governmental regulation and the enforcement thereof that may materially restrict or adversely affect how we conduct business and our financial results; • Weather conditions, including potential impacts, if any, from climate change, known and unknown, and natural disasters or unusual weather events; • International conflicts and disputes, such as the ongoing conflict between Russia and Ukraine, the war between Israel and Hamas and the broader regional conflict in the Middle East, which restrict our ability to supply products into affected regions, due to the corresponding effects on demand, the application of international sanctions, or practical consequences on transportation, banking transactions, and other commercial activities in troubled regions; • Compliance with the FCPA and other anti-corruption laws or trade control laws, as well as other laws governing our operations; • Risks associated with pandemics and other public health emergencies; • The number, type, outcomes (by judgment or settlement) and costs of legal, tax, regulatory or administrative proceedings, litigation and/or amnesty programs; • Increased scrutiny from stakeholders related to environmental, social and governance ("ESG") matters, as well as our ability to achieve our broader ESG goals and objectives; • Costs and timing of implementation of any upgrades or changes to our information technology systems; • Failure by us to comply with any privacy or data security laws or to protect against theft of customer, employee and corporate sensitive information; • Information technology system failures, data security breaches, network disruptions, and cybersecurity events; and • Other factors described elsewhere in this document and from time to time in documents that we file with the SEC.
Risk Factors of this report, as well as the following factors: • Risks associated with the implementation of our strategic growth initiatives, including diversification, and the Company's understanding of, and entry into, new industries and technologies; • Risks associated with acquisitions, dispositions, strategic transactions and global asset realignment initiatives of Mativ; • Risks related to the impairment of goodwill; • Adverse changes in our end-market sectors impacting key customers; • Changes in the source and intensity of competition in our commercial end-markets; • Adverse changes in sales or production volumes, pricing and/or manufacturing costs; • Seasonal or cyclical market and industry fluctuations which may result in reduced net sales and operating profits during certain periods; • Risks associated with our technological advantages in our intellectual property and the likelihood that our current technological advantages are unable to continue indefinitely; • Supply chain disruptions, including the failure of one or more material suppliers, including energy, resin, fiber, and chemical suppliers, to supply materials as needed to maintain our product plans and cost structure; • Increases in operating costs due to inflation and continuing increases in the inflation rate or otherwise, such as labor expense, compensation and benefits costs; • Our ability to attract and retain key personnel, labor shortages, labor strikes, stoppages or other disruptions; • Changes in general economic, financial and credit conditions in the U.S., Europe, China and elsewhere, including the impact thereof on currency exchange rates (including any weakening of the Euro) and on interest rates; • A failure in our risk management and/or currency or interest rate swaps and hedging programs, including the failures of any insurance company or counterparty; • Changes in the manner in which we finance our debt and future capital needs, including potential acquisitions; • Changes in tax rates, the adoption of new U.S. or international tax legislation or exposure to additional tax liabilities; • Uncertainty as to the long-term value of the common stock of Mativ; • Changes in employment, wage and hour laws and regulations in the U.S. and elsewhere, including unionization rules and regulations by the National Labor Relations Board, equal pay initiatives, additional anti-discrimination rules or tests and different interpretations of exemptions from overtime laws; 48 • The impact of tariffs, and the imposition of any future additional tariffs and other trade barriers, and the effects of retaliatory trade measures; • Existing and future governmental regulation and the enforcement thereof that may materially restrict or adversely affect how we conduct business and our financial results; • Weather conditions, including potential impacts, if any, from climate change, known and unknown, and natural disasters or unusual weather events; • International conflicts and disputes, such as the ongoing conflict between Russia and Ukraine, and regional conflict in the Middle East, which restrict our ability to supply products into affected regions, due to the corresponding effects on demand, the application of international sanctions, or practical consequences on transportation, banking transactions, and other commercial activities in troubled regions; • Compliance with the FCPA and other anti-corruption laws or trade control laws, as well as other laws governing our operations; • Risks associated with pandemics and other public health emergencies; • The number, type, outcomes (by judgment or settlement) and costs of legal, tax, regulatory or administrative proceedings, litigation and/or amnesty programs; • Increased scrutiny from stakeholders related to environmental, social and governance ("ESG") matters, as well as our ability to achieve our broader ESG goals and objectives; • Costs and timing of implementation of any upgrades or changes to our information technology systems; • Failure by us to comply with any privacy or data security laws or to protect against theft of customer, employee and corporate sensitive information; • Risks and uncertainties associated with the introduction of AI, machine learning, and process automation, including rapid technological change, evolving regulatory frameworks, data quality and security, and reliance on third‑party AI tools or vendors; • Information technology system failures, data security breaches, network disruptions, and cybersecurity events; and • Other factors described elsewhere in this document and from time to time in documents that we file with the SEC.
"Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the U.S. Securities and Exchange Commission on February 29, 2024. Other Factors affecting Liquidity and Capital Resources Debt Interest Obligations.
"Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the U.S. Securities and Exchange Commission on February 27, 2025. Other Factors affecting Liquidity and Capital Resources Debt Interest Obligations.
Per the terms of the Company's amended Credit Agreement, net leverage was 4.4 at December 31, 2024, versus a current maximum covenant ratio of 5.50x. The Company’s nearest debt maturities are our Revolving Credit Facility, Term Loan A Facility, and Delayed Draw Term Loan Facility, due on May 6, 2027.
Under the terms of the Company's amended Credit Agreement, net leverage was 4.2 at December 31, 2025, versus a current maximum covenant ratio of 5.50x. The Company’s nearest debt maturities are our Revolving Credit Facility, Term Loan A Facility, and Delayed Draw Term Loan Facility, due on May 6, 2027.
Commitments and Contingencies of the Notes to Consolidated Financial Statements. 36 Property, Plant and Equipment Valuation Certain of our manufacturing processes are capital intensive; as a result, we make substantial investments in property, plant and equipment which are recorded at cost. Net property, plant and equipment comprised 25% of our total assets as of December 31, 2024.
Commitments and Contingencies of the Notes to Consolidated Financial Statements. 37 Property, Plant and Equipment Valuation Certain of our manufacturing processes are capital intensive; as a result, we make substantial investments in property, plant and equipment which are recorded at cost. Net property, plant and equipment comprised 30% of our total assets as of December 31, 2025.
In December 2024, the Company further amended its Credit Agreement to increase the applicable rate margin to 2.75% with respect to revolving loans and delayed draw term loans borrowed at the adjusted Term SOFR rate, adjusted EURIBOR rate or Daily Simple RFR rate, as applicable, and letter of credit fees, 1.75% with respect to revolving loans and delayed draw term loans borrowed at the ABR rate, 3.00% with respect to Term A Loans borrowed at the adjusted Term SOFR rate or adjusted EURIBOR rate, as applicable, and 2.00% with respect to Term A Loans borrowed at the ABR rate and the commitment fee rate to 0.45%, in each case, when the net debt to EBITDA ratio is greater than or equal to 5.00 to 1.00.
Additionally, we added a $650.0 million delayed draw term loan facility (the "Delayed Draw Term Loan Facility"). 44 In December 2024, the Company amended its Credit Agreement to increase the applicable rate margin to 2.75% with respect to revolving loans and delayed draw term loans borrowed at the adjusted Term SOFR rate, adjusted EURIBOR rate or Daily Simple RFR rate, as applicable. , and letter of credit fees, 1.75% with respect to revolving loans and delayed draw term loans borrowed at the ABR rate, 3.00% with respect to Term A Loans borrowed at the adjusted Term SOFR rate or adjusted EURIBOR rate, as applicable, and 2.00% with respect to Term A Loans borrowed at the ABR rate and the commitment fee rate to 0.45%, in each case, when the net debt to EBITDA ratio is greater than or equal to 5.00 to 1.00.
Forward-looking statements include, without limitation, those regarding the incurrence of additional debt and expected maturities of the Company’s debt obligations, the adequacy of our sources of liquidity and capital, acquisition integration and growth prospects (including international growth), the cost and timing of our restructuring actions, the impact of ongoing litigation matters and environmental claims, the amount of capital spending and/or common stock repurchases, future cash flows, purchase accounting impacts, impacts and timing of our ongoing operational excellence and other cost-reduction and cost-optimization initiatives, profitability, and cash flow, the expected benefits and accretion of the Neenah merger and Scapa acquisition and integration, whether the strategic benefits of the EP Divestiture can be achieved and other statements generally identified by words such as "believe," "expect," "intend," "guidance," "plan," "forecast," "potential," "anticipate," "confident," "project," "appear," "future," "should," "likely," "could," "may," "will," "typically" and similar words.
Forward-looking statements include, without limitation, those regarding the incurrence of additional debt and expected maturities of the Company’s debt obligations, the adequacy of our sources of liquidity and capital, acquisition integration and growth prospects (including international growth), the cost and timing of our restructuring actions, the impact of ongoing litigation matters and environmental claims, the amount of capital spending and/or common stock repurchases, future cash flows, purchase accounting impacts, impacts and timing of our ongoing operational excellence and other cost-reduction and cost-optimization initiatives, profitability, and cash flow, statement regarding the strategic benefits of divestitures, statements regarding the impact of tariffs and trade actions and other statements generally identified by words such as "believe," "expect," "intend," "guidance," "plan," "forecast," "potential," "anticipate," "confident," "project," "appear," "future," "should," "likely," "could," "may," "will," "typically" and similar words.
The annual impairment test performed on October 1, 2024, 2023 and 2022 resulted in no impairment. We continue to monitor the impact of the sustained impact of macro-economic conditions, an increasingly global competitive environment, along with continued volatility in the construction and automotive sectors.
The annual impairment tests performed on October 1, 2025, 2024 and 2023 resulted in no impairment charges. We continue to monitor the impact of the sustained impact of macro-economic conditions, an increasingly global competitive environment, along with continued volatility particularly in the construction and automotive sectors.
In the year ended December 31, 2024, net changes in operating working capital increased cash flow by $0.1 million primarily related to changes in accounts payable and other current liabilities and accounts receivable, partially offset by an increase in inventories.
In 2024, net changes in operating working capital increased cash flow by $0.1 million primarily related to changes in accounts payable and other current liabilities and accounts receivable, partially offset by an increase in inventories.
For more information on the goodwill impairment, refer to Note 10. Goodwill of the Notes to Consolidated Financial Statements. The Company incurred restructuring and other impairment charges of 37 $38.1 million and $22.6 million, in 2024 and 2023, respectively, primarily related to exiting certain product categories and site closures.
For more information on the goodwill impairment, refer to Note 9. Goodwill of the Notes to Consolidated Financial Statements. The Company incurred restructuring and other impairment charges of $19.9 million and $38.1 million, in 2025 and 2024, respectively, primarily related to exiting certain product categories and site closures.
The weighted average effective interest rate on our debt facilities, including the impact of hedges, was approximately 6.41% and 5.98% for the years-ended December 31, 2024 and 2023, respectively.
The weighted average effective interest rate on our debt facilities, including the impact of hedges, was approximately 7.46% and 6.41% for the years-ended December 31, 2025 and 2024, respectively.
A major factor in our liquidity and capital resource planning is our generation of cash flow from operations, which is sensitive to changes in the mix of products sold, volume and pricing of our products, as well as changes in our production volumes, costs and working capital.
Securities and Exchange Commission on February 27, 2025. 42 LIQUIDITY AND CAPITAL RESOURCES Liquidity & Cash Flow A major factor in our liquidity and capital resource planning is our generation of cash flow from operations, which is sensitive to changes in the mix of products sold, volume and pricing of our products, as well as changes in our production volumes, costs and working capital.
Subject to certain conditions, including the absence of a default or event of default under the Credit Agreement, the Company may request incremental loans to be extended under the Revolving Credit Facility or as additional Term Loan Facilities so long as the Company is in pro forma compliance with the financial covenants set forth in the Credit Agreement and the aggregate of such increases does not exceed $400.0 million.
Subject to certain conditions, the Company may request incremental loans to be extended under the Revolving Credit Facility or as additional Term Loan Facilities so long as the Company is in pro forma compliance with the required financial covenants and the aggregate of such increases does not exceed $400.0 million. Refer to Note 12.
Borrowings under the Term Loan B Facility in Euros will bear interest equal to EURIBOR (subject to a minimum floor of 0%) plus 3.75%.
Borrowings under the Term Loan B Facility will bear interest, equal to a forward-looking term rate based on Term SOFR (subject to a minimum floor of 0.75%) plus 2.75%. Borrowings under the Term Loan B Facility in Euros will bear interest equal to EURIBOR (subject to a minimum floor of 0%) plus 3.75%.
The Indenture provides that interest on the 2029 Notes will accrue from October 7, 2024 and is payable semi-annually in arrears on April 1 and October 1 of each year, beginning on April 1, 2025, and the 2029 Notes mature on October 1, 2029, subject to earlier repurchase or redemption.
Interest on the 2029 Notes is payable semi-annually in arrears on April 1 and October 1 of each year, beginning on April 1, 2025, and the 2029 Notes mature on October 1, 2029, subject to earlier repurchase or redemption.
Debt Instruments and Related Covenants The following table presents activity related to our debt instruments for the years-ended (in millions): Years Ended December 31, 2024 2023 Proceeds from long-term debt $ 531.0 $ 241.0 Payments on long-term debt (554.7) (834.6) Net (payments) proceeds from borrowings $ (23.7) $ (593.6) Net payments from borrowings were $23.7 million during the year ended December 31, 2024 compared to net payments from borrowings of $593.6 million during the prior year-end.
The following table presents activity related to our debt instruments for the years-ended (in millions): Years Ended December 31, 2025 2024 Proceeds from long-term debt $ 82.0 $ 531.0 Payments on long-term debt (161.9) (554.7) Net payments on borrowings $ (79.9) $ (23.7) Net payments from borrowings were $79.9 million during the year ended December 31, 2025 compared to net payments from borrowings of $23.7 million during the prior year-end.
RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS For a discussion regarding recently adopted accounting pronouncements, refer to Recently adopted Accounting Pronouncements included in Note 2. Summary of Significant Accounting Policies of the Notes to Consolidated Financial Statements. SUMMARY In 2024, we reported a net loss of $48.7 million on total net sales of $1,981.1 million.
RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS For a discussion regarding recently adopted accounting pronouncements, refer to Recently adopted Accounting Pronouncements included in Note 2. Summary of Significant Accounting Policies of the Notes to Consolidated Financial Statements. 38 SUMMARY In 2025, we reported a net loss of $337.4 million on total net sales of $1,987.0 million.
Net Loss and Loss per Share Net loss in the year ended December 31, 2024 was $48.7 million, or $0.90 per diluted share, compared to net loss of $507.7 million, or $9.33 per diluted share, during the prior year period.
Net Loss and Loss per Share Net loss in the year ended December 31, 2025 was $337.4 million, or $6.19 per diluted share, compared to net loss of $48.7 million, or $0.90 per diluted share, during the prior year period.
Debt interest obligations as of December 31, 2024 amount to $281.7 million over the next five years, Approximately $83.2 million, $83.1 million, and $56.0 million is due annually in 2025, 2026, and 2027, respectively, with the remainder being due in 2028 and 2029. Other Obligations.
Debt interest obligations as of December 31, 2025 amount to $185.0 million over the next five years, Approximately $73.6 million, $52.2 million, and $34.9 million is due annually in 2026, 2027, and 2028, respectively, with the remainder being due in 2029 and 2030. Other Obligations.
Gross Profit The following table presents gross profit (in millions): Percent Change Percent of Net Sales 2024 2023 Change 2024 2023 Net sales $ 1,981.1 $ 2,026.0 $ (44.9) (2.2) % 100.0 % 100.0 % Cost of products sold 1,617.0 1,670.2 (53.2) (3.2) % 81.6 % 82.4 % Gross profit $ 364.1 $ 355.8 $ 8.3 2.3 % 18.4 % 17.6 % Gross profit of $364.1 million during the year ended December 31, 2024 increased $8.3 million, or 2.3%, compared to the prior year period which reflected favorable relative net selling price and input cost performance, partially offset by lower volume/mix.
Gross Profit The following table presents gross profit (in millions): Percent Change Percent of Net Sales 2025 2024 Change 2025 2024 Net sales $ 1,987.0 $ 1,981.1 $ 5.9 0.3 % Cost of products sold 1,624.1 1,617.0 7.1 0.4 % 81.7 % 81.6 % Gross profit $ 362.9 $ 364.1 $ (1.2) (0.3) % 18.3 % 18.4 % Gross profit of $362.9 million during the year ended December 31, 2025 decreased $1.2 million, or 0.3%, compared to the prior year period which reflected higher distribution and manufacturing costs, and lower volume/mix, partially offset by favorable relative net selling price and input cost performance.
In connection with the Merger, we further amended our Credit Agreement on May 6, 2022 in order to extend the maturity of the Revolving Credit Facility and the Term Loan A Facility to May 6, 2027, and to increase the availability under the Revolving Credit Facility, subject to consummation of the Merger, to $600.0 million.
On May 6, 2022 the Company amended its Credit Agreement to extend the maturity of the Revolving Credit Facility and the Term Loan A Facility to May 6, 2027, and to increase the availability under the Revolving Credit Facility to $600.0 million.
The applicable margin for borrowings under the revolving credit agreement is expected to range from 1.00% to 2.75% for SOFR loans and EURIBOR loans, and from 0.00% to 1.75% for base rate loans, in each case, depending on the Company’s then current net debt to EBITDA ratio. 44 Borrowings under the Term Loan B Facility will bear interest, equal to a forward-looking term rate based on Term SOFR (subject to a minimum floor of 0.75%) plus 2.75%.
The applicable margin for borrowings under the revolving credit agreement is expected to range from 1.00% to 2.75% for SOFR loans and EURIBOR loans, and from 0.00% to 1.75% for base rate loans, in each case, depending on the Company’s then current net debt to EBITDA ratio.
Under the terms of the amended Credit Agreement, Mativ will continue to be required to maintain certain financial ratios and comply with certain financial covenants, as amended by the Amendment, including a requirement (a) to maintain a minimum interest coverage ratio of 2.50 to 1.00 over each consecutive four fiscal quarter period ending December 31, 2024 through December 31, 2025 with a step-up to 2.75 to 1.00 for each such period thereafter and (b) to maintain a maximum net debt to EBITDA ratio of 5.50 to 1.00 over each consecutive four fiscal quarter period ending December 31, 2024 through December 31, 2025 with a step-down to 5.25 to 1.00 for each such period thereafter.
Under the terms of the amended Credit Agreement, Mativ must maintain certain financial ratios and comply with certain financial covenants , including a requirement (a) to maintain a minimum interest coverage ratio of 2.50 to 1.00 over each consecutive four fiscal quarter period ending December 31, 2024 through December 31, 2025 with a step-up to 2.75 to 1.00 for each such period thereafter and (b) to maintain a maximum net debt to EBITDA ratio of 5.50 to 1.00 over each consecutive four fiscal quarter period ending December 31, 2024 through December 31, 2025 with a step-down to 5.25 to 1.00 for each such period thereafter. borrowings and loans made under the amended Credit Agreement are secured by substantially all of the Company’s and the guarantors’ personal property, excluding certain customary items of collateral, and will be guaranteed by the Company’s existing and future wholly-owned direct material domestic subsidiaries and by Mativ Luxembourg (formerly known as SWM Luxembourg).
Changes to the forecasted revenue growth, earnings before income taxes, depreciation and amortization (“EBITDA”), net debt, and benefits from Merger synergies may result in a significantly different estimate of our forecasted financial covenant ratios. Our total debt to capital ratios, as calculated under the amended Credit Agreement, at December 31, 2024 and December 31, 2023 were 55.9% and 53.8%, respectively.
Changes to the forecasted revenue growth, earnings before income taxes, depreciation and amortization (“EBITDA”), net debt, and benefits from future synergies may result in a significantly different estimate of our forecasted financial covenant ratios.
We have certain purchase obligations as of December 31, 2024, under which we are required to make minimum payments for goods and services including raw materials, capital projects and energy. These obligations amount to approximately $100.6 million of which $84.3 million is obligated over the next year and the remainder is obligated over the next five years.
We have certain purchase obligations as of December 31, 2025, under which we are required to make minimum payments for goods and services including raw materials, capital projects and energy.
Compared to the prior year, net sales decreased $44.9 million, or 2.2%. Sales reflected lower volumes including volumes associated with closed and divested facilities (-1.3%) and lower selling prices (-1.1%). FAM segment net sales decreased $43.5 million, or 5.4%, compared to prior year primarily driven by lower volume (-3.7%) and lower selling prices (-1.9%).
Compared to the prior year, net sales increased $5.9 million, or 0.3%. Sales reflected higher volume/mix, favorable currency translation, and higher selling prices, partially offset by sales associated with exited facilities. FAM segment net sales increased $1.0 million, or 0.1%, compared to prior year primarily driven by favorable currency translation, partially offset by lower selling prices.
Income Taxes The $30.2 million benefit and $26.8 million expense for income taxes in the years-ended December 31, 2024 and 2023, respectively, resulted in an effective tax rate of 38.3% compared with (5.6)% in the prior year. The net change was primarily due a non-deductible goodwill impairment in the prior period, and a change in a valuation allowance.
Income Taxes The $125.6 million benefit and $30.2 million benefit for income taxes in the years-ended December 31, 2025 and 2024, respectively, resulted in an effective tax rate of 27.1% compared with 38.3% in the prior year.
During the year ended December 31, 2023, we performed an interim quantitative goodwill impairment test, which resulted in a non-cash impairment charge of $401.0 million related to certain reporting units which are now included in the SAS reportable segment. Refer to Note 10. Goodwill, of the Notes to Consolidated Financial Statements for additional information.
During the years ended December 31, 2025 and 2023, we performed interim quantitative goodwill impairment tests, which resulted in non-cash impairment charges of $411.9 million and $401.0 million, respectively. Refer to Note 9. Goodwill, of the Notes to Consolidated Financial Statements for additional information.
The balance under the Term Loan B Facility was $116.5 million as of December 31, 2024.
Debt of the Notes to Consolidated Financial Statements for additional information about the Term Loan B Facility. The balance under the Term Loan B Facility was $116.5 million as of December 31, 2025.
FAM segment net sales of $766.5 million during the year ended December 31, 2024 decreased $43.5 million, or 5.4% compared to prior year-end. Sales reflected lower volume (-3.7%) and lower selling prices (-1.9%). SAS segment net sales of $1,214.6 million during the year ended December 31, 2024 decreased $1.4 million, or 0.1% compared to the prior year-end.
Sales reflected favorable currency translation, offset by lower selling prices. SAS segment net sales of $1,219.5 million during the year ended December 31, 2025 increased $4.9 million, or 0.4% compared to the prior year-end. Sales reflected higher volume/mix, higher selling prices, and favorable currency translation, partially offset by sales associated with exited facilities.
Nonmanufacturing Expenses The following table presents nonmanufacturing expenses (in millions): Percent Change Percent of Net Sales 2024 2023 Change 2024 2023 Selling and general expense $ 233.8 $ 263.9 $ (30.1) (11.4) % 11.8 % 13.0 % Research and development expense 23.0 21.2 1.8 8.5 % 1.2 % 1.0 % Intangible asset amortization expense 62.9 61.0 1.9 3.1 % 3.2 % 3.0 % Nonmanufacturing expenses $ 319.7 $ 346.1 $ (26.4) (7.6) % 16.2 % 17.0 % Nonmanufacturing expenses of $319.7 million during the year ended December 31, 2024 decreased $26.4 million, or 7.6%, compared to the prior year period primarily driven by lower integration related and divestiture costs, and savings from the Plan. 39 Restructuring and Other Impairment Expense The following table presents restructuring and other impairment expense by segment (in millions): Percent of Net Sales 2024 2023 Change 2024 2023 FAM $ 5.7 $ 2.8 $ 2.9 0.7 % 0.4 % SAS 29.0 19.4 9.6 2.4 % 1.6 % Unallocated expenses 3.4 0.4 3.0 Total $ 38.1 $ 22.6 $ 15.5 1.9 % 1.1 % The Company incurred total restructuring and other impairment expense of $38.1 million in the year ended December 31, 2024, compared to $22.6 million in the year ended December 31, 2023, an increase of $15.5 million.
FAM gross profit decreased $10.9 million, or 6.3% and SAS gross profit increased $9.7 million, or 5.1%. 40 Nonmanufacturing Expenses The following table presents nonmanufacturing expenses (in millions): Percent Change Percent of Net Sales 2025 2024 Change 2025 2024 Selling and general expense $ 228.7 $ 233.8 $ (5.1) (2.2) % 11.5 % 11.8 % Research and development expense 23.6 23.0 0.6 2.6 % 1.2 % 1.2 % Intangible asset amortization expense 63.2 62.9 0.3 0.5 % 3.2 % 3.2 % Nonmanufacturing expenses $ 315.5 $ 319.7 $ (4.2) (1.3) % 15.9 % 16.2 % Nonmanufacturing expenses of $315.5 million during the year ended December 31, 2025 decreased $4.2 million, or 1.3%, compared to the prior year period primarily due to lower selling and general expense as a result of actions taken under an organizational realignment initiative ("the Plan").
SAS segment net sales decreased $1.4 million, or 0.1%, compared to prior year primarily driven by lower selling prices (-0.6%), partially offset by higher volume (2.3%) net of closed and divested facilities (-2.0%). The decrease in net loss in 2024 compared to 2023 was primarily due to the $401.0 million goodwill impairment recorded in the prior period.
SAS segment net sales increased $4.9 million, or 0.4%, compared to prior year primarily driven by higher volume/mix, higher selling prices, and favorable currency translation, partially offset by sales associated with exited facilities. The increase in net loss in 2025 compared to 2024 was primarily due to the $411.9 million goodwill impairment expense.
In 2023, net changes in operating working capital decreased cash flow by $19.8 million primarily related to decreases in accounts payable and other current liabilities. Cash Provided by (Used in) Investing Cash used in investing activities in the year ended December 31, 2024 was $44.7 million compared to $61.4 million in the prior year.
In the year ended December 31, 2025, net changes in operating working capital increased cash flow by $8.4 million primarily related to changes in inventories and accounts payable and other current liabilities, partially offset by an increase in accounts receivable.
Discontinued Operations of the Notes to Consolidated Financial Statements for more information on the discontinued operation and transaction. 35 CRITICAL ACCOUNTING ESTIMATES We disclose those accounting estimates that we consider to be significant in determining the amounts to be utilized for communicating our consolidated financial position, results of operations and cash flows in the first note to our consolidated financial statements included elsewhere herein.
Although we are continuing to monitor the impact of such announcements, as well as opportunities to mitigate their related impacts, costs and other effects associated with the tariffs remain uncertain. 36 CRITICAL ACCOUNTING ESTIMATES We disclose those accounting estimates that we consider to be significant in determining the amounts to be utilized for communicating our consolidated financial position, results of operations and cash flows in the first note to our consolidated financial statements included elsewhere herein.
The covenants contained in our Indenture and amended Credit Agreement, each, as defined below in "Debt Instruments and Related Covenants," require that we maintain certain financial ratios, as disclosed in Note 13. Debt of the Notes to Consolidated Financial Statements, none of which under normal business conditions materially limit our ability to pay such dividends.
The Company is subject to covenants, discussed below, which require that we maintain certain financial ratios none of which under normal business conditions materially limit our ability to pay such dividends.
Indenture for 8.00% Senior Unsecured Notes Due 2029 On October 7, 2024, the Company closed a private offering of $400.0 million of 8.000% senior unsecured notes due 2029 (the “2029 Notes”).
Our total debt to capital ratios, as calculated under the amended Credit Agreement, at December 31, 2025 and December 31, 2024 were 67.1% and 55.9%, respectively. 45 Indenture for 8.00% Senior Unsecured Notes Due 2029 On October 7, 2024, the Company closed a private offering of $400.0 million of 8.000% senior unsecured notes due 2029 (the “2029 Notes”).
For both segments, we expect our long-term growth outlook to be driven by macro factors affecting our served end-markets, as well as industry demand for many of our key applications.
These obligations amount to approximately $105.1 million of which $84.3 million is obligated over the next year and the remainder is obligated over the next five years. 46 OUTLOOK For both Filtration & Advanced Materials (FAM) and Sustainable & Adhesive Solutions (SAS) segments, we expect our long-term growth outlook to be driven by macro factors affecting our served end-markets, as well as industry demand for many of our key applications.
Dividend Payments We have declared and paid cash dividends on our common stock every fiscal quarter since the second quarter of 1996. On February 19, 2025, we announced a cash dividend of $0.10 per share payable on March 28, 2025, to stockholders of record as of the close of business on March 14, 2025.
On February 18, 2026, we announced a cash dividend of $0.10 per share payable on March 27, 2026, to stockholders of record as of the close of business on March 13, 2026.
Cash used in investing activities for the current and prior years were mainly attributable to capital spending. Cash Provided by (Used in) Financing Activities Cash used in financing activities in the year ended December 31, 2024 was $55.9 million compared to used in financing activities of $662.0 million in the prior year.
Cash used in investing activities decreased $19.7 million during the year ended December 31, 2025 compared to the prior year and was attributable to lower capital spending. Cash used in financing activities increased $50.8 million during the year ended December 31, 2025 compared to the prior year.
In the SAS segment, operating profit in the year ended December 31, 2024 was $45.4 million, an increase of $421.7 million, compared to operating loss of $376.3 million in the year ended December 31, 2023. The increase was 40 primarily driven by the 2023 $401.0 million goodwill impairment. For more information on the goodwill impairment, refer to Note 10.
In the SAS segment, operating profit in the year ended December 31, 2025 was $85.6 million, an increase of $40.2 million, compared to operating profit of $45.4 million in the year ended December 31, 2024.
Operating Profit (Loss) The following table presents operating profit (loss) by segment (in millions): Percent Change Return on Net Sales 2024 2023 Change 2024 2023 FAM $ 70.0 $ 99.3 $ (29.3) (29.5) % 9.1 % 12.3 % SAS 45.4 (376.3) 421.7 N.M. 3.7 % (30.9) % Unallocated expenses (109.1) (136.9) 27.8 (20.3) % Total $ 6.3 $ (413.9) $ 420.2 N.M. 0.3 % (20.4) % Operating profit was $6.3 million in the year ended December 31, 2024, compared to a loss of $413.9 million in the year ended December 31, 2023, an increase of $420.2 million.
Total severance related expenses during the year ended December 31, 2025 are primarily attributable to actions taken under the second wave of the Plan. Operating Profit (Loss) The following table presents operating profit (loss) by segment (in millions): Percent Change Return on Net Sales 2025 2024 Change 2025 2024 FAM $ (359.8) $ 70.0 $ (429.8) N.M.
In the FAM segment, operating profit in the year ended December 31, 2024 was $70.0 million compared to operating profit of $99.3 million in the year ended December 31, 2023, a decrease of $29.3 million driven by lower volumes in advanced films and netting, and unfavorable relative net selling price versus input cost performance, partially offset by higher volumes in filtration, and lower selling and general expenses.
Goodwill of the Notes to Consolidated Financial Statements. Excluding the goodwill impairment, operating profit was $52.1 million, a $17.9 million decrease from the prior year due to higher manufacturing and distribution costs, and unfavorable relative net selling price and input cost performance, partially offset by higher volume/mix, and lower selling and general expenses.
Our liquidity is supplemented by funds available under our Revolving Facility with a syndicate of banks that is used as either operating conditions or strategic opportunities warrant. Cash Requirements As of December 31, 2024, $78.2 million of our $94.3 million of cash and cash equivalents was held by foreign subsidiaries.
Our liquidity is supplemented by funds available under our Revolving Facility with a syndicate of banks that is used as either operating conditions or strategic opportunities warrant and also by our Receivables Sales Agreement, refer to Note 5. Accounts Receivable, Net for additional information. Market conditions permitting, we may also seek to access the capital markets as we deem appropriate.
Other Income (Expense), Net Other income (expense), net was expense of $3.2 million in the year ended December 31, 2024 compared to expense of $4.8 million for the year ended December 31, 2023, a decrease in expense of $1.6 million. The decrease in expense was driven by fewer legal and tax settlements in the current period.
Other Expense, Net Other expense was $7.5 million in the year ended December 31, 2025 compared to expense of $3.2 million for the year ended December 31, 2024, an increase in expense of $4.3 million. The current period includes non-cash settlement charges associated with our U.S. Pension Plan and higher foreign currency losses.
Cash Provided by Operations Net cash provided by operations was $94.8 million in the year ended December 31, 2024, compared with $76.6 million in the prior year. The increase was related to lower net loss adjusted for non-cash items and favorable year-over-year movements in working capital related cash flows.
The increase was attributable to lower cash payments related to restructuring activities and favorable year-over-year movements in working capital related cash flows.
Interest expense increased mainly due to higher average balances and higher average rates on the floating portion of our outstanding debt in 2024, as well as the impact from hedges and the allocation of a portion of our interest expense to Discontinued Operations in 2023.
Interest Expense Interest expense was $71.1 million in the year ended December 31, 2025, a decrease of $3.6 million, or 4.8%, compared to the year ended December 31, 2024. Interest expense decreased mainly due to lower average balances on the floating portion of our outstanding debt in 2025.
The gain and cash proceeds are subject to customary working capital adjustments during a specified period following the sale close date. 41 LIQUIDITY AND CAPITAL RESOURCES Liquidity & Debt Overview As of December 31, 2024, the Company had $1,089.3 million of total debt, a decrease of $15.3 million year over year, $94.3 million of cash, and undrawn capacity on its $600.0 million revolving line of credit facility (the "Revolving Facility") of $356.4 million.
Debt Instruments and Related Covenants As of December 31, 2025, the Company had $1,018.2 million of total debt, a decrease of $71.1 million year over year, $84.2 million of Cash and cash equivalents, and undrawn capacity of $431.2 million on its Revolving Credit Facility (as defined below).
Cash paid for income taxes (net of refunds) was $14.9 million for the year ended December 31, 2024.
Cash Requirements As of December 31, 2025, $74.9 million of our $84.2 million of cash and cash equivalents was held by foreign subsidiaries. Restricted cash of $5.6 million primarily represents retained contributions associated with our UK Pension scheme. Cash paid for income taxes (net of refunds) was $11.5 million for the year ended December 31, 2025.